Progyny, Inc.

NASDAQ:PGNY

Medical - Healthcare Information Services

Healthcare
$36.16 -0.19%

-$0.05 today

Market cap
$2.66B
Beta
1.04
P/E (TTM)
31.4
EPS (TTM)
$0.84
52W Low $16.10High $28.75

Volume 0.88M

Average 1.49M

PGNY Common Stock Repurchased

Cash spent buying back the company's own shares.

Progyny, Inc.NASDAQ: PGNY

Common Stock Repurchased · Q2 FY2026 · quarter ended Jun 2026

Common stock repurchased turns negative

Q2 FY2026 common stock repurchased was -$148.63M, compared with $0 a year earlier. Trailing-twelve-month common stock repurchased was -$348.89M.

Context

  • Common stock repurchased amounted to 6.3% of revenue in FY2025, down 19.4 pp from a year earlier.
  • Common stock repurchased increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly common stock repurchased holds near -$148.63M or moves back toward the trailing-twelve-month quarterly average of -$87.22M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$148.63M+25.3% QoQ
Last fiscal yearDec 2025
-$81.66M-72.8% YoY
LTMJun 2026
-$348.89M+199.3% YoY
Common Stock Repurchased past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-72.8%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Common Stock Repurchased history

USD · from the cash flow

Latest · FY2025
(81.66M) USD
Year-over-year change
+72.8%

Common Stock Repurchased vs competitors

How PGNY compares with its peers on the latest reported figures

  • PGNY's LTM Jun 2026 common stock repurchased of $348.89M is the 2nd largest of the 3 companies compared; the peer median is $202.25M.
  • Its year-over-year change of +199.3% is the highest of 2, against a peer median of +63.6%.
  • Common stock repurchased amounts to 26.6% of revenue for PGNY, versus a peer median of 14.8%.
PGNY Competitors Peer median
Common Stock Repurchased for PGNY and competitors
Company Period LTM YoY 3-year CAGR% of revenue
HQYHealthEquity, Inc.LTM Jul 2026$404.5M +63.6%—29.7%
PGNYProgyny, Inc.LTM Jun 2026$348.89M +199.3%—26.6%
OMDAOmada HealthLTM Mar 2026$0 ——0.0%
Peer median (excluding PGNY) $202.25M+63.6%—14.8%

Competitors are the stored peer set for PGNY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income65.77M30.36M62.04M54.34M58.52M
Depreciation & Amortization1.3M1.6M2.28M3.18M4.95M
Deferred Income Tax(33.3M)(6.62M)3.75M(10.46M)(8.12M)
Stock-Based Compensation33.71M100.75M122.61M128.13M131.87M
Change in Working Capital(51.26M)(59.49M)(17.42M)(11.78M)2.8M
Accounts Receivables(68.68M)(119.3M)(21.74M)(9.87M)(5.12M)
Inventory00000
Accounts Payables17.84M47.69M16.24M(30.27M)28.75M
Other Working Capital(421K)12.12M(11.92M)28.37M(20.84M)
Other Non-Cash Items9.82M13.79M15.56M15.7M20.17M
Operating Cash Flow26.04M80.4M188.81M179.11M210.19M
Capital Expenditures(2.13M)(3.24M)(3.64M)(5.41M)(18.41M)
Acquisitions (Net)000(5.3M)(9.34M)
Purchases of Investments(111.48M)(163.33M)(429.69M)(170.34M)(354.96M)
Sales of Investments122.37M122.71M232.81M376.84M223.7M
Other Investing Activities00000
Investing Cash Flow8.77M(43.87M)(200.53M)195.79M(159.01M)
Debt Repayment00000
Common Stock Issued4.27M4.23M6.13M2.4M1.23M
Common Stock Repurchased000(300.28M)(81.66M)
Dividends Paid00000
Other Financing Activities(17.97M)(12.09M)(17.2M)(12M)(18.94M)
Financing Cash Flow(13.7M)(7.86M)(11.07M)(309.88M)(99.36M)
Effect of Forex Changes001K1K62K
Net Change in Cash21.11M28.67M(22.78M)65.02M(48.12M)
Free Cash Flow23.91M77.15M185.17M173.7M191.78M

Progyny, Inc.

NASDAQ:PGNY

Intrinsic Alpha fair value

Locked

Current Price

$36.16

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.